Status:
COMPLETED
A Single-Arm Study Evaluating the Effectiveness and Safety of Suzetrigine (SUZ) for Acute Pain After Aesthetic or Reconstructive Surgeries
Lead Sponsor:
Vertex Pharmaceuticals Incorporated
Conditions:
Acute Pain
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The purpose of this study to evaluate the effectiveness, safety, and tolerability of SUZ as part of multimodal therapy (MMT) in treating acute postoperative pain.
Eligibility Criteria
Inclusion
- Key
- Body mass index (BMI) of greater than or equal to (≥)18.0 to less than or equal to (≤) 40.0 kilogram per meter square (kg/m\^2)
- Participants scheduled to undergo an aesthetic or reconstructive surgical procedure that would typically be treated with opioid therapy for at least 72 hours postoperatively
- Key
Exclusion
- • Participated in a previous study with SUZ or received Journavx
- Other protocol defined Inclusion/Exclusion criteria may apply.
Key Trial Info
Start Date :
March 21 2025
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 7 2025
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT06887972
Start Date
March 21 2025
End Date
November 7 2025
Last Update
December 15 2025
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Atlanta Center for Medical Research
Atlanta, Georgia, United States, 30331
2
Beth Israel Deaconess Medical Center - Surgery
Boston, Massachusetts, United States, 02215
3
HD Research LLC | First Surgical Hospital
Bellaire, Texas, United States, 77401
4
Memorial Hermann Village
Houston, Texas, United States, 77043